Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Symptoms of psoriatic arthritis are similar to rheumatoid arthritis and include, pain, swelling and stiffness in one or more ...

Psoriatic arthritis surgery could involve removing damaged tissue or bone or replacing a joint with severe damage. Learn more ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

The following is a summary of “Opioid Use and Healthcare Utilization in Adults With Psoriatic Arthritis and Ankylosing ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

FDA approval of IMULDOSA was granted based on a comprehensive clinical development program. The data showed that IMULDOSA is similar to its reference product STELARA in terms of pharmacokinetic ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.